GlassScriptPhysician profile
Neil Maitra
NPI 1073142675
$3,351.26
in general payments reported to CMS, 2019-2025
25 companies · $1,844 in 2025
The $1,844 reported for 2025 was more than what 82% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $246 · 2024: $1,261 · 2025: $1,844.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,082 · Education: $269.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,082.41 |
| Education | $268.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $705.61 | 2024-2025 | Ensite, Portico, Dragonfly Opstar |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $420.69 | 2024-2025 | Lifevest |
| Medtronic, INC. | $372.69 | 2023-2025 | Onyx Frontier, Symplicity G3, Azure Xt Dr Mri Surescan |
| Novartis Pharmaceuticals Corporation | $269.96 | 2024-2025 | |
| Boston Scientific Corporation | $261.20 | 2024 | Avvigo Guidance System, Accolade Sr, Lux-Dx Insertable Cardiac Monitor |
| Kestra Medical Technology Services, INC. | $252.94 | 2024-2025 | Assure Wcd |
| Shockwave Medical, INC | $155.65 | 2025 | |
| Bridgebio Pharma, INC. | $128.47 | 2025 | Attruby |
| Merck Sharp & Dohme LLC | $120.25 | 2025 | Winrevair |
| Cook Medical LLC | $107.85 | 2024 | Micropuncture |
| Kiniksa Pharmaceuticals International, Plc | $100.13 | 2024 | Arcalyst |
| Irhythm Technologies, INC. | $63.76 | 2023-2024 | Zio Xt Patch, Zio Monitor |
| Philips North America LLC | $57.54 | 2023-2024 | (Ck4) Mcot |
| Cvrx, INC. | $41.72 | 2024-2025 | Barostim Neo System |
| Astrazeneca Pharmaceuticals LP | $38.52 | 2024-2025 | Wainua, Farxiga |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $37.20 | 2024-2025 | |
| Lantheus Medical Imaging, INC. | $34.42 | 2024 | |
| Abiomed | $33.40 | 2025 | |
| Pfizer INC. | $29.39 | 2025 | |
| Novo Nordisk INC | $24.30 | 2024 | Ozempic, Rybelsus |
| Esperion Therapeutics, INC. | $23.39 | 2024 | Nexletol |
| Alnylam Pharmaceuticals INC. | $21.43 | 2025 | Amvuttra |
| Baxter Healthcare | $17.89 | 2024 | Hillrom - Cardiac Ambulatory Monitor |
| Actelion Pharmaceuticals US, INC. | $16.99 | 2025 | Uptravi, Opsumit |
| Kiniksa Pharmaceuticals, LTD. | $15.87 | 2023 | Arcalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neil Maitra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.